Veru Inc.
NASDAQ:VERU · NASDAQ Capital Market
+$0.13 today
Vol 0.69M · Avg 1.82M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-124.0%
avg -90.1%
ROIC
-108.5%
avg -57.0%
ROA
-76.2%
avg -44.6%
Analysis
ROA is currently the strongest return metric at -76.2% versus its period average of -44.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Mitchell S. Steiner | Chairman, President & Chief Executive Officer | $1.49M | — | 65 | $604,000.00 | 3.76% |
K. Gary Barnette | Chief Scientific Officer | $896,079.00 | — | 58 | $160,000.00 | 1.00% |
Harry Fisch | Vice Chairman & Chief Corporate Officer | $724,488.00 | — | 67 | $160,000.00 | 1.00% |
Michele Greco | Chief Financial Officer & Chief Administrative Officer | $493,703.00 | — | 67 | $164,000.00 | 1.02% |
Martin Tayler | Executive Vice President of FC2 Global Operations | $180,512.00 | — | 57 | $39,844.00 | 0.25% |
Gary Bird | Executive Vice President of Quality & Regulatory Affairs | — | — | — | $160,000.00 | 1.00% |
Kevin J. Gilbert | Executive Vice President of Corporate Development | — | — | — | $97,335.00 | 0.61% |
Philip R. Greenberg | Executive VP, General Counsel & Secretary | — | — | — | — | — |
Samuel Fisch | Executive Director of Investor Relations & Corporate Communications | — | — | — | $160,000.00 | 1.00% |
Domingo Rodriguez | Executive Vice President of Global Clinical Operations | — | — | 64 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -34.3% | N/A1 analysts |
| Revenue | N/A | N/A | -2.4% | N/A0 analysts |
| Net Income | N/A | N/A | -34.3% | N/A0 analysts |
| EBIT | N/A | N/A | -15.4% | N/A0 analysts |
Analysis
Recent growth has been strongest in Revenue at -2.4% over three years.
Competitors
Peer companies in the same sector
MAIA Biotechnology, Inc.
AMEX:MAIA
$82.69M
PolyPid Ltd.
PYPD
$47.54M
BioXcel Therapeutics, Inc.
BTAI
$35.82M
Mural Oncology plc
MURA
$35.38M
Annovis Bio, Inc.
ANVS
$35.02M
RenovoRx, Inc.
RNXT
$32.97M
Dyadic International, Inc.
DYAI
$29.00M
Celularity Inc.
CELU
$18.52M
BioAtla, Inc.
BCAB
$4.56M
Reviva Pharmaceuticals Holdings, Inc.
RVPH
$2.35M
Who manages VERU?
Veru Inc. (VERU) lists 10 active executives. The top listed executive is Mitchell S. Steiner, Chairman, President & Chief Executive Officer.
Are VERU insiders buying or selling?
Recent insider activity shows net buying of $25.12M.
Explore More
Continue the stock analysis
Jump to another research area for this company.